Verve Therapeutics, Inc. (VERV) Tops Q4 EPS by 10c

Verve Therapeutics, Inc. (NASDAQ: VERV) reported Q4 EPS of ($0.58), $0.10 better than the analyst estimate of ($0.68). Revenue for the quarter came in at $13.08 million versus the consensus estimate of $3.57 million.

For earnings history and earnings-related data on Verve Therapeutics, Inc. (VERV) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• EU approves Arrowhead's plozasiran for rare triglyceride disorder
• Texas AG Paxton announces ongoing investigation into Carnival over data breach